AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is preparing to submit its first targeted cancer drug from a new portfolio for regulatory approval. The company showcased advances across its cancer portfolio at the European Society for Medical Oncology Congress in Madrid, presenting data that included late-stage trial results for a stomach cancer drug. According to trial data, the experimental drug extended overall survival and doubled survival time in certain CLDN 18.2-positive gastric cancer patients. Company executives maintained that the phase 3 antibody-drug conjugate data remains robust enough for regulators despite a progression-free survival miss.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ AstraZeneca is preparing to file the first of a new portfolio of targeted cancer drugs for regulatory approval.
- ✓ AstraZeneca reported positive clinical trial results at the European Society for Medical Oncology Congress 2026 in Madrid.
- ✓ Late-stage trial data showed that AstraZeneca's stomach cancer drug extended overall survival and doubled survival time in certain CLDN 18.2-positive gastric cancer patients.
- ✓ An AstraZeneca executive insisted that phase 3 antibody-drug conjugate data is robust enough for regulators despite a progression-free survival miss.
What changed
AstraZeneca prepared to file its first new targeted cancer drug for regulatory approval and showcased trial data at the European Society for Medical Oncology Congress.
Live updates
-
AstraZeneca Prepares Regulatory Filings for Targeted Cancer Drugs
AstraZeneca is preparing to submit its first targeted cancer drug from a new portfolio for regulatory approval. The company showcased advances across its cancer portfolio at the European Society for Medical Oncology Congress in Madrid, presenting data that included late-stage trial results for a stomach cancer drug. According to trial data, the experimental drug extended overall survival and doubled survival time in certain CLDN 18.2-positive gastric cancer patients. Company executives maintained that the phase 3 antibody-drug conjugate data remains robust enough for regulators despite a progression-free survival miss.
Why it matters
The European Society for Medical Oncology Congress in Madrid serves as the backdrop for AstraZeneca to highlight its pipeline developments. The company is working to cement its market position with new targeted therapies. Regulatory filings for the portfolio represent a critical step toward commercializing these treatments.
What is confirmed
- AstraZeneca is preparing to file the first of a new portfolio of targeted cancer drugs for regulatory approval.
- AstraZeneca reported positive clinical trial results at the European Society for Medical Oncology Congress 2026 in Madrid.
- Late-stage trial data showed that AstraZeneca's stomach cancer drug extended overall survival and doubled survival time in certain CLDN 18.2-positive gastric cancer patients.
- An AstraZeneca executive insisted that phase 3 antibody-drug conjugate data is robust enough for regulators despite a progression-free survival miss.
What to watch next
- Official regulatory submissions for the targeted cancer drug portfolio
- Further regulatory responses regarding the phase 3 antibody-drug conjugate data
confidence 100%Sources used for this update (13)
- WSJ — AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
- Reuters — AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds
- Fierce Biotech — ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss
- STAT — At ESMO, AstraZeneca’s cancer pursuits get a showcase
- Bloomberg.com — Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
- GenomeWeb — AstraZeneca’s Antibody-Drug Conjugate Improves Survival in Certain CLDN 18.2-Positive Gastric Cancer Patients
- NDTV — AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Trial
- FirstWord Pharma — ESMO26: AstraZeneca's Claudin 18.2-targeting ADC doubles OS in gastric cancer
- www.marketscreener.com — Daiichi Sankyo Posts Higher H1 Attributable Profit, Revenue Up
- www.marketscreener.com — Daiichi Sankyo Company, Limited Reaffirms Earnings Guidance for the Full Fiscal Year 2026
- www.marketscreener.com — AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | MarketScreener
- ca.marketscreener.com — AstraZeneca highlights advances across cancer portfolio at ESMO 2026 | MarketScreener Canada
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community